| 000137 (2011) |
Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Shen-Yang Lim [Malaisie] ; Bernard Ravina [États-Unis] ; Klaus Seppi [Autriche] ; Miguel Coelho [Portugal] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease |
| 001498 (2005) |
Christopher G. Goetz [États-Unis] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal] | Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004 |
| 000992 (2009) |
Samyra H. J. Keus [Pays-Bas] ; Marten Munneke [Pays-Bas] ; Maarten J. Nijkrake [Pays-Bas] ; Gert Kwakkel [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas] | Physical therapy in Parkinson's disease: Evolution and future challenges |
| 001055 (2007) |
Samyra H. J. Keus [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas] ; Erik J. M. Hendriks [Pays-Bas] ; Alexandra B. Bredero-Cohen [Pays-Bas] ; Marten Munneke [Pays-Bas] | Evidence‐based analysis of physical therapy in Parkinson's disease with recommendations for practice and research |
| 000136 (2011) |
Klaus Seppi [Autriche, Portugal] ; Daniel Weintraub [États-Unis] ; Miguel Coelho [Portugal] ; Santiago Perez-Lloret [France] ; Susan H. Fox [Canada] ; Regina Katzenschlager [Autriche] ; Eva-Maria Hametner [Autriche] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Christopher G. Goetz [États-Unis] ; Cristina Sampaio [Portugal] | The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease |
| 000525 (2010) |
Samyra H. J. Keus [Pays-Bas] ; Maarten J. Nijkrake [Pays-Bas] ; George F. Borm [Pays-Bas] ; Gert Kwakkel [Pays-Bas] ; Raymund A. C. Roos [Pays-Bas] ; Henk W. Berendse [Pays-Bas] ; Eddy M. Adang [Pays-Bas] ; Sebastiaan Overeem [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas] ; Marten Munneke [Pays-Bas] | The ParkinsonNet trial: Design and baseline characteristics |
| 000C37 (2008) |
Olalla Bello [Espagne] ; Jose Andres Sanchez [Espagne] ; Miguel Fernandez-Del-Olmo [Espagne] | Treadmill walking in Parkinson's disease patients: Adaptation and generalization effect |
| 000C96 (2008) |
A. H. V. Schapira [Royaume-Uni] | Progress in neuroprotection in Parkinson’s disease |
| 001400 (2005) |
Silvi Frenkel-Toledo [Israël] ; Nir Giladi [Israël] ; Chava Peretz [Israël] ; Talia Herman [Israël] ; Leor Gruendlinger [Israël] ; Jeffrey M. Hausdorff [Israël, États-Unis] | Treadmill walking as an external pacemaker to improve gait rhythm and stability in Parkinson's disease |
| 000197 (2011) |
Atbin Djamshidian [Royaume-Uni] ; Francisco Cardoso [Brésil] ; Donald Grosset [Royaume-Uni] ; Henrietta Bowden-Jones [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Pathological gambling in Parkinson's disease—a review of the literature |
| 000254 (2011) |
Olivier Rascol [France] ; Andres Lozano [Canada] ; Matthew Stern [États-Unis] ; Werner Poewe [Autriche] | Milestones in Parkinson's disease therapeutics |
| 000280 (2011) |
Maria Milenkova [Allemagne, Bulgarie] ; Bahram Mohammadi [Allemagne] ; Katja Kollewe [Allemagne] ; Christoph Schrader [Allemagne] ; Anja Fellbrich [Allemagne] ; Matthias Wittfoth [Allemagne] ; Reinhard Dengler [Allemagne] ; Thomas F. Münte [Allemagne] | Intertemporal choice in Parkinson's disease |
| 000284 (2011) |
Maria Papathanou [Suède] ; Sarah Rose [Royaume-Uni] ; Andrew Mccreary [Pays-Bas] ; Peter Jenner [Royaume-Uni] | Induction and expression of abnormal involuntary movements is related to the duration of dopaminergic stimulation in 6‐OHDA‐lesioned rats |
| 000291 (2011) |
Polly Ambermoon [Australie] ; Adrian Carter [Australie] ; Wayne D. Hall [Australie] ; Nadeeka N. W. Dissanayaka [Australie] ; John D. O'Sullivan [Australie] | Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field |
| 000333 (2011) |
Olivier Rascol [France] | Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release |
| 000417 (2011) |
Shearwood Mcclelland Iii [États-Unis] | A cost analysis of intraoperative microelectrode recording during subthalamic stimulation for Parkinson's disease |
| 000534 (2010) |
Adrian P. Fawcett [Canada] ; Esther G. González [Canada] ; Elena Moro ; Martin J. Steinbach [Canada] ; Andres M. Lozano [Canada] ; William D. Hutchison [Canada] | Subthalamic Nucleus Deep Brain Stimulation Improves Saccades in Parkinson's Disease |
| 000681 (2010) |
Sean S. O'Sullivan [Royaume-Uni] ; Atbin Djamshidian [Royaume-Uni, Autriche] ; Zeshan Ahmed [Royaume-Uni] ; Andrew H. Evans [Australie] ; Andrew D. Lawrence [Royaume-Uni] ; Janice L. Holton [Royaume-Uni] ; Tamas Revesz [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] | Impulsive‐compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy |
| 000970 (2009) |
Luigi M. Romito [Italie] ; Maria Fiorella Contarino [Italie] ; Nicola Vanacore [Italie] ; Anna Rita Bentivoglio [Italie] ; Massimo Scerrati [Italie] ; Alberto Albanese [Italie] | Replacement of dopaminergic medication with subthalamic nucleus stimulation in Parkinson's disease: Long‐term observation |
| 000B48 (2009) |
Frank Andersohn [Allemagne] ; Edeltraut Garbe [Allemagne] | Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists |
| 000B50 (2009) |
Louis C. S. Tan [Singapour] ; Kenneth K. C. Ng [Singapour] ; Wing-Lok Au [Singapour] ; Raymond K. K. Lee [Singapour] ; Yiong-Huak Chan [Singapour] ; Nigel C. K. Tan [Singapour] | Bromocriptine use and the risk of valvular heart disease |
| 000B70 (2009) |
Maarten J. Nijkrake [Pays-Bas] ; Samyra H. J. Keus [Pays-Bas] ; Rob A. B. Oostendorp [Pays-Bas] ; Sebastiaan Overeem [Pays-Bas] ; Wim Mulleners [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas] ; Marten Munneke [Pays-Bas] | Allied health care in Parkinson's disease: Referral, consultation, and professional expertise |
| 000C36 (2008) |
Fabrizio Stocchi [Italie] ; Michele Tagliati [États-Unis] ; C. Warren Olanow [États-Unis] | Treatment of levodopa‐induced motor complications |
| 000C98 (2008) |
Peter Jenner [Royaume-Uni] | Preventing and controlling dyskinesia in Parkinson's disease—A view of current knowledge and future opportunities |
| 000D26 (2008) |
Frank J. M. Van Eijkeren [Pays-Bas] ; Ruud S. J. Reijmers [Pays-Bas] ; Mirjam J. Kleinveld [Pays-Bas] ; Angret Minten [Pays-Bas] ; Jan Pieter Ter Bruggen [Pays-Bas] ; Bastiaan R. Bloem [Pays-Bas] | Nordic walking improves mobility in Parkinson's disease |
| 000D72 (2008) |
Shen-Yang Lim [Canada] ; Andrew H. Evans [Australie] ; Janis M. Miyasaki [Canada] | Impulse Control and Related Disorders in Parkinson's Disease |
| 000F33 (2007) |
Charlene Hoffman Snyder [États-Unis] ; Charles H. Adler [États-Unis] | The patient with Parkinson’s disease: Part I–Treating the motor symptoms;Part II–Treating the nonmotor symptoms |
| 001035 (2007) |
Claudio Lucetti [Italie] ; Paulo Del Dotto [Italie] ; Gianna Gambaccini [Italie] ; Roberto Ceravolo [Italie] ; Chiara Logi [Italie] ; Caterina Berti [Italie] ; Giuseppe Rossi [Italie] ; Maria Cristina Bianchi [Italie] ; Michela Tosetti [Italie] ; Luigi Murri [Italie] ; Ubaldo Bonuccelli [Italie] | Influences of dopaminergic treatment on motor cortex in Parkinson disease: A MRI/MRS study |
| 001050 (2007) |
Anthony H. V. Schapira [Royaume-Uni] | Future directions in the treatment of Parkinson's disease |
| 001185 (2006) |
Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France] | The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease |
| 001207 (2006) |
M. Horstink [Pays-Bas] ; E. Tolosa [Espagne] ; U. Bonuccelli [Italie] ; G. Deuschl [Allemagne] ; A. Friedman [Pologne] ; P. Kanovsky [République tchèque] ; J. P. Larsen [Norvège] ; A. Lees [Royaume-Uni] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; C. Sampaio [Portugal] | Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease |
| 001315 (2006) |
Daniel Oved [Israël] ; Ilan Ziv [Israël] ; Therese A. Treves [Israël] ; Diana Paleacu [Israël] ; Eldad Melamed [Israël] ; Ruth Djaldetti [Israël] | Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease |
| 001318 (2006) |
C. Vossius [Norvège] ; M. Gjerstad [Norvège] ; H. Baas [Allemagne] ; J. P. Larsen [Norvège] | Drug costs for patients with Parkinson's disease in two different European countries |
| 001402 (2005) |
Meg Morris [Australie] ; Robert Iansek [Australie] ; Jennifer Mcginley [Australie] ; Thomas Matyas [Australie] ; Frances Huxham [Australie] | Three‐dimensional gait biomechanics in Parkinson's disease: Evidence for a centrally mediated amplitude regulation disorder |
| 001442 (2005) |
A H V. Schapira | Present and future drug treatment for Parkinson’s disease |
| 001584 (2004) |
Connie Marras [Canada] ; Anthony Lang [Canada] ; Murray Krahn [Canada] ; George Tomlinson [Canada] ; Gary Naglie [Canada] | Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations |
| 001607 (2004) |
Padraig E. O'Suilleabhain [États-Unis] ; Teodoro Bottiglieri [États-Unis] ; Richard B. Dewey Jr. [États-Unis] ; Shailja Sharma [États-Unis] ; Ramon Diaz-Arrastia [États-Unis] | Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease |
| 001648 (2004) |
Matthew B. Stern [États-Unis] ; Kenneth L. Marek [États-Unis] ; Joseph Friedman [États-Unis] ; Robert A. Hauser [États-Unis] ; Peter A. Lewitt [États-Unis] ; Daniel Tarsy [États-Unis] ; C. Warren Olanow [États-Unis] | Double‐blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients |
| 001709 (2003) |
Matthew A. Brodsky [États-Unis] ; James Godbold [États-Unis] ; Tom Roth [États-Unis] ; C. Warren Olanow [États-Unis] | Sleepiness in Parkinson's disease: A controlled study |
| 001710 (2003) |
Sebastian Paus [Allemagne] ; Hans Michael Brecht [Allemagne] ; Jürgen Köster [Allemagne] ; Gert Seeger [Allemagne] ; Thomas Klockgether [Allemagne] ; Ullrich Wüllner [Allemagne] | Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease |
| 001750 (2003) |
Birgit Högl [Autriche] ; Klaus Seppi [Autriche] ; Elisabeth Brandauer [Autriche] ; Susanne Glatzl [Autriche] ; Birgit Frauscher [Autriche] ; Ulrike Niedermüller [Autriche] ; Gregor Wenning [Autriche] ; Werner Poewe [Autriche] | Increased daytime sleepiness in Parkinson's disease: A questionnaire survey |
| 001784 (2003) |
A. Albanese [Italie] ; C. Colosimo [Italie] | Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists |
| 001820 (2002) |
Tamar C. Rubinstein [Israël] ; Nir Giladi [Israël] ; Jeffrey M. Hausdorff [Israël, États-Unis] | The power of cueing to circumvent dopamine deficits: A review of physical therapy treatment of gait disturbances in Parkinson's disease |
| 001C62 (2000) |
B. Bergamasco ; L. Frattola ; A. Muratorio ; F. Piccoli ; F. Mailland ; L. Parnetti | Alpha‐dihydroergocryptine in the treatment of de novo parkinsonian patients: results ofa multicentre, randomized, double‐blind, placebo‐controlled study |
| 001D61 (1999) |
Martin Goulet ; Marc Morissette ; Richard Grondin ; Pierre Falardeau ; Paul J. Bédard ; William Rostène [France] ; Thérèse Di Paolo | Neurotensin receptors and dopamine transporters: Effects of MPTP lesioning and chronic dopaminergic treatments in monkeys |
| 001F85 (1997) |
Satu-Mari Kokko [Finlande] ; Jaana Paltamaa [Finlande] ; Erja Ahola [Finlande] ; Esko M Lki [Finlande] | The assessment of functional ability in patients with Parkinson's disease: The PLM‐test and three clinical tests |
